Omacor ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-004404-21-GB (EUCTR) | 10/12/2004 | 17/02/2005 | Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus | Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences - Fish oils in Lupus | Systemic Lupus Erythematosus | Trade Name: Omacor Product Name: Omacor INN or Proposed INN: Eicosapentaenoic acid INN or Proposed INN: Docosahexaenoic acid INN or Proposed INN: alpha-tocopherol | GreenPark Healthcare Trust | Queens University Belfast | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | United Kingdom |